Hepatic and glucagon-like peptide-1–mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors
J. Clin. Invest. Kyle W. Sloop, et al. 113:1571 doi:10.1172/JCI20911 [
Go to this article.]
Figure 7GCGR ASO treatment does not result in adverse hypoglycemia in nondiabetic mice. Nonfasted plasma glucose in 11-week-old male
db+/? mice, which had been treated twice per week (every 3.5 days) by subcutaneous injection with control ASO 141923 (gray bars) or GCGR ASO 180475 (white bars) at 25 mg/kg for a total of 9 doses. Plasma glucose was analyzed in samples obtained from different groups of five animals, which were random fed (6:00 AM sampling) or fasted for 6, 12, or 24 hours (fasting started at 6:00 AM). Data are the mean values ± SEM of five mice per treatment group. Significant differences (
P < 0.05) were observed in the fed state and after a 12 hour fast.
